Optinose surges on Paratek Pharma's buyout deal for up to $330 million
Shares of drug developer Optinose OPTN.O rise 56.5% to an over four-month high of $9.60
*OPTN is set for biggest percentage gain on record
OPTN says privately held Paratek Pharmaceuticals will acquire co and its nasal spray, Xhance, for up to $330 million
Xhance is used for treating a type of long-term sinus and nasal passage inflammation called chronic rhinosinusitis
Deal offers potential consideration of up to $14 per share, including upfront consideration of $9 per share, which represents 50% premium to stock's last close
Up to last close, OPTN down 76.7% in past 12 months
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey







